Prosemble kicked off London Life Sciences Week with a strong presence at the Cancer Tech Accelerator Innovators Forum. Judy Kingswolf-Yamakawa presented our advancements in protein nanoparticles and AI toxicity platforms, alongside leading oncology and ecosystem partners. The pitch was well-received, garnering strong engagement from representatives of the Institute of Cancer Research and the Royal Marsden. We also connected with key stakeholders, including Angela Kukula (MedCity), Macmillan Cancer Support, and David Harland (AstraZeneca). These discussions have strengthened our position within the UK cancer innovation landscape and provided new opportunities to collaborate for patient impact.